Live Chat
Today's Hours: 8:00am - 10:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Book
    Association of American Medical Colleges.
    Summary: "This landmark publication published by the AAMC identifies a list of integrated activities to be expected of all M.D. graduates making the transition from medical school to residency. This guide delineates 13 Entrustable professional activities (EPAs) that all entering residents should be expected to perform on day 1 of residency without direct supervision regardless of specialty choice. The Core EPAs for entering residency are designed to be a subset of all of the graduation requirements of a medical school. Individual schools may have additional mission-specific graduation requirements, and specialties may have specific EPAs that would be required after the student has made the specialty decision but before residency matriculation. The Core EPAs may also be foundational to an EPA for any practicing physician or for specialty-specific EPAs"--Publisher's description.

    Contents:
    Gather a history and perform a physical examination
    Prioritize a differential diagnosis following a clinical encounter
    Recommend and interpret common diagnostic and screening tests
    Enter and discuss orders and prescriptions
    Document a clinical encounter in the patient record
    Provide an oral presentation of a clinical encounter
    Form clinical questions and retrieve evidence to advance patient care
    Give or receive a patient handover to transition care responsibility
    Collaborate as a member of an interprofessional team
    Recognize a patient requiring urgent or emergent care and initiate evaluation and management
    Obtain informed consent for tests and/or procedures
    Perform general procedures of a physician
    Identify system failures and contribute to a culture of safety and improvement.
    Digital Access R2Library 2014
  • Article
    Singh BN, Ellrodt G, Peter CT.
    Drugs. 1978 Mar;15(3):169-97.
    Verapamil is a novel antiarrhythmic and antianginal agent which, although introduced in 1962, has only recently gained prominence not only as a significant agent in cardiovascular therapeutics but also as a powerful tool to examine the nature of some of the biophysical phenomena at the membrane of cardiac and other excitable tissues. Verapamil is the prototype of those agents which selectively inhibit membrane transport of calcium, an action which accounts for the drug's peripheral and coronary vasodilator properties, its effect on excitation-contraction coupling and hence its negative inotropic propensity, as well as its depressant effects on the sinus node and atrioventricular conduction. Its pharmacological effects are largely independent of the autonomic nervous system. The main therapeutic uses of the drug are in the management of atrial tachyarrhythmias, angina, and possibly hypertension. The overall exp:rimental and clinical data suggest that verapamil will become an important and safe addition to existing drug regimens, especially as an agent of choice for the short-term treatment of most cases of paroxysmal supraventricular tachycardias. The initial experience in other arrhythmias, angina and hypertension, is also sufficiently encouraging to justify further detailed clinical trials to define its potential role in cardiovascular therapeutics.
    Digital Access Access Options